Clinical Trial Update: Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating apixaban for reducing restenosis and limb loss in critical limb ischemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Science Valley Research Institute | Conditions: Critical Limb Ischemia | Phase 3 | Status: UNKNOWN